TP53 and neoplasm: The frequency of aberrant TP53 expression in our study was 19.2% among the diffuse-type tumours, which is quite similar to the observed frequencies of 26.1–27.5% [3, 4] but notably different from 53.8% reported by Kim et al. (2016).